Eledon Pharmaceuticals Stock Today

ELDN Stock  USD 2.70  0.05  1.89%   

Performance

9 of 100

 
Weak
 
Strong
OK

Odds Of Distress

Less than 43

 
High
 
Low
Below Average
Eledon Pharmaceuticals is selling at 2.70 as of the 20th of July 2024; that is 1.89 percent increase since the beginning of the trading day. The stock's open price was 2.65. Eledon Pharmaceuticals has about a 43 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Eledon Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 20th of June 2024 and ending today, the 20th of July 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
17th of September 2014
Category
Healthcare
Classification
Health Care
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis , and requiring an organ or cell-based transplant. Eledon Pharmaceuticals, Inc. The company has 38.51 M outstanding shares of which 170.62 K shares are currently shorted by private and institutional investors with about 1.01 trading days to cover. More on Eledon Pharmaceuticals

Moving against Eledon Stock

  0.69HEPA Hepion PharmaceuticalsPairCorr
  0.68BMY Bristol Myers Squibb Earnings Call This WeekPairCorr
  0.39VKTX Viking Therapeutics Earnings Call This WeekPairCorr
  0.37XFOR X4 PharmaceuticalsPairCorr
  0.31ENVB Enveric BiosciencesPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Eledon Stock Highlights

ESG Sustainability
Environmental
Governance
Social
Chief PresidentSteven Perrin
Thematic IdeaPharmaceutical Products (View all Themes)
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover5.0E-45.0E-4
Fairly Down
Slightly volatile
Total Current Liabilities3.7 M3.9 M
Notably Down
Slightly volatile
Non Current Liabilities Total40.5 M38.6 M
Sufficiently Up
Slightly volatile
Total Assets81.1 M125.9 M
Way Down
Slightly volatile
Total Current Assets56 M56.1 M
Slightly Down
Slightly volatile
Debt Levels
Eledon Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Eledon Pharmaceuticals' financial leverage. It provides some insight into what part of Eledon Pharmaceuticals' total assets is financed by creditors.
Liquidity
Eledon Pharmaceuticals currently holds 383 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Eledon Pharmaceuticals has a current ratio of 21.78, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Eledon Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Depreciation

392,700
Eledon Pharmaceuticals (ELDN) is traded on NASDAQ Exchange in USA. It is located in 19900 MacArthur Boulevard, Irvine, CA, United States, 92612 and employs 20 people. Eledon Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 102.04 M. Eledon Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 38.51 M outstanding shares of which 170.62 K shares are currently shorted by private and institutional investors with about 1.01 trading days to cover. Eledon Pharmaceuticals currently holds about 70.46 M in cash with (39.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.12, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Eledon Pharmaceuticals Probability Of Bankruptcy
Ownership Allocation
30% of Eledon Pharmaceuticals outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change.
Check Eledon Ownership Details

Eledon Stock Institutional Holders

InstituionRecorded OnShares
State Street Corporation2024-03-31
44.7 K
Northern Trust Corp2024-03-31
39.8 K
Blackrock Inc2024-03-31
26.8 K
Marco Investment Management Llc2024-03-31
24.8 K
Mercer Global Advisors Inc.2024-03-31
16.7 K
Charles Schwab Investment Management Inc2024-03-31
15 K
Millennium Management Llc2024-03-31
13.9 K
Pathstone Holdings Llc2024-03-31
13 K
Tower Research Capital Llc2024-03-31
5.7 K
Bvf Inc2024-03-31
4.3 M
Armistice Capital, Llc2024-03-31
2.3 M
View Eledon Pharmaceuticals Diagnostics

Eledon Pharmaceuticals Historical Income Statement

At this time, Eledon Pharmaceuticals' Interest Expense is very stable compared to the past year. As of the 20th of July 2024, Total Other Income Expense Net is likely to grow to about 2.8 M, while Depreciation And Amortization is likely to drop about 355.3 K. View More Fundamentals

Eledon Stock Against Markets

Eledon Pharmaceuticals Corporate Management

Gregory FlesherConsultantProfile
Bryan JDCorporate CounselProfile
John HerbergerVice OperationsProfile
Paul LittleCFO OfficerProfile
David HovlandChief OfficerProfile
FACS FACSChief OfficerProfile

Additional Information and Resources on Investing in Eledon Stock

When determining whether Eledon Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eledon Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eledon Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eledon Pharmaceuticals Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eledon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.
You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eledon Pharmaceuticals. If investors know Eledon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eledon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.23)
Return On Assets
(0.33)
Return On Equity
(0.53)
The market value of Eledon Pharmaceuticals is measured differently than its book value, which is the value of Eledon that is recorded on the company's balance sheet. Investors also form their own opinion of Eledon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eledon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eledon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eledon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eledon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eledon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eledon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.